This article is a commentary on:
Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery
Lukas Andereggen
Emanuel Christ- 1Department of Neurosurgery, Kantonsspital Aarau, Aarau, Switzerland
- 2Faculty of Medicine, University of Bern, Bern, Switzerland
- 3Department of Endocrinology, Diabetology and Metabolism, University Hospital of Basel, Basel, Switzerland
A Commentary on
Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery
By Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P. Front. Endocrinol. (2020) 11:439. doi: 10.3389/fendo.2020.00439
We read with great interest the article by Zielinski et al. (1) reporting indicators for early remission (i.e., 3 months) after transsphenoidal surgery in 48 prolactinoma patients resistant to or intolerant of dopamine agonists (DAs). The only independent predictor for early remission was missing cavernous sinus invasion (p<0.001) (1), for which radiological assessment of Knosp grades is advised. The Knosp classification is used to describe invasiveness of an adenoma into the cavernous sinus (2, 3). In grade 0, the adenoma does not extend the medial carotid line; in grade 1, the adenoma extends to the medial carotid line; in grade 2, the adenoma extends beyond the median carotid line; in grade 3, the adenoma extends to the lateral carotid line; and in grade 4, the internal carotid artery is completely surrounded by the adenoma (2). The higher the grading, the more difficult complete surgical removal can be attained (2). In surgical series, the Knosp grading not only plays an important role in controlling hyperprolactinemia in patients with DA resistance or intolerance (4). Likewise, in patients with a surgical first approach, missing cavernous sinus invasion (i.e., Knosp grade ≤1) is pivotal to attain high remission rates along with the avoidance of ongoing DA therapy (5–7).
Significant predictors of DA resistance have been identified as male gender, large adenomas, and prolonged time to prolactin (PRL) normalization (8, 9). In contrast to the patient cohort included in Zielinski et al.’s study (1), many patients with evidence of DA resistance or intolerance are thus men and present with larger prolactinomas and/or adenomas with invasion of the cavernous sinus (i.e., Knosp grade ≥2) (10–12). Namely, in women, amenorrhea is investigated early on whereas men with hypogonadism often suffer from more nonspecific symptoms, subsequently presenting at older age with larger and/or invasive adenomas at the time of diagnosis (12–14). Thus, it has been proposed that surgery be discussed in men because of a higher likelihood of DA resistance and aggressive behavior of prolactinoma (15), although men with prolactinomas usually respond to medical treatment with no need for any additional treatment (16). In Zielinski et al.’s reported cohort, the majority of patients harbored a microadenoma or adenoma with a Knosp grade of ≤1 (1). In this selected patient cohort, however, we consider that a primary surgical approach might at least be interdisciplinary discussed as an alternative to DA-agonist therapy. There is a good chance of non-dependency on DA therapy in dedicated pituitary centers using a surgical-first approach in patients with adenomas not infiltrating the cavernous sinus (i.e., Knosp grade ≤1) (7). Namely, after a median follow-up of ≈7 years, we noted that DA therapy was ultimately required in 24% of patients with microprolactinomas, compared to 49% with macroprolactinomas (p = 0.03). As for the latter, DA was required in 76% with Knosp grade 1 compared to 29% with Knosp grade 0 macroprolactinomas (p = 0.004) (7).
Furthermore, prior DA therapy may induce adenoma fibrosis, potentially hampering surgical remission rates (17, 18). While cabergoline has a better drug tolerance profile and allows for easier administration thanks to its longer half-life (19–21), it is the preferred drug when it comes to medical treatment of prolactinomas (22). It has been reported that prolactinomas exposed to bromocriptine may develop tumor fibrosis (18, 23–29), yet rarely after cabergoline (18, 30). Menucci et al. reported that patients exposed to bromocriptine are more likely to have tumor fibrosis than patients that are untreated or treated with cabergoline alone (18). Namely, in 21 prolactinoma patients with DA therapy, adenoma fibrosis was noted in 83% when treated with bromocriptine, and in 22% of patients treated with cabergoline, with a statistically significant difference in patients exposed to bromocriptine for at least one month (p< 0.05) (18). Given that bromocriptine was prescribed in 75% of all patients in the Zielinski study cohort (1), and that a Knosp grade 0 and 1 was noted in 80% of patients (1), this is a strong argument that in this selected cohort a first line approach might have been a valuable treatment option, in particular as tumor fibrosis hampers complete adenoma resection, especially after bromocriptine therapy (18, 23–29).
Besides, in prolactinoma patients, the assessment of long-term outcomes is pivotal. As DAs can be tapered 24 months after initiation of medical therapy when prolactin (PRL) levels are normalized (31), early recurrence of hyperprolactinemia following discontinuation of DAs have been reported, particularly in patients with macroprolactinomas (32–35). However, macroprolactinomas per se do not impede low remission rates, but rather does their extension into the cavernous sinus (7). As for surgical series, recurrences are observed in one-third of prolactinoma patients and may occur as late as 13 years after surgery (10). It has been shown that hyperprolactinemia recurs early in most macroprolactinomas (93%) and microprolactinomas (64%) following DA therapy discontinuation, while cessation of DA cannot be recommended even after 7 years of therapy (36). A recent meta-analysis, however, showed that long-term remission was lower after DA withdrawal (34%) than after transsphenoidal surgery (64%) (37), while a previous meta-analysis reported even lower (21%) long-term remission rates after DA withdrawal (38). While we noted that recurrence-free intervals were significantly shorter in patients with a Knosp grade 1 adenoma (110.5 ± 32.2 months) than in those with a Knosp grade 0 adenoma (365.4 ± 22.9 months; log-rank test, p<0.001), recurrence-free intervals did not differ significantly with regard to adenoma size (7). In this regard, reporting the number of patients who remain off medication is an important outcome measure, as surgery is a known effective alternative treatment option in patients who are intolerant or resistant to medical therapy (39).
Furthermore, the long-term sequelae of cumulative DA doses might become an argument for surgery in younger patients (15, 40–43). Although side effects of DAs are infrequently encountered, Ono and colleagues reported that up to 18% of patients needed persistent high-dose cabergoline treatment in order to normalize hyperprolactinemia, irrespective of prolactinoma size (44). In this regard, cumulative doses of DA might account for long-term adverse effects (40–42), and new concerns about long-term safety of DAs have emerged over time in multiple studies (15, 41, 45, 46). DAs have been associated with side effects such as nausea, dizziness, and postural hypotension (20). Although side effects of cabergoline were recorded in 68% of women in a large cohort with hyperprolactinemic amenorrhea, only 3% of them ultimately had to discontinue drug therapy due to intolerance (19). Also, cabergoline-associated valvulopathy is uncommon (47, 48), and its clinical significance remains unclear (49). However, with regard to persistent DA therapy in the long term, cumulative DA doses might become an argument for surgery in younger patients (15, 40–43). In addition, personality changes associated with DAs have been reported, including gambling, hypersexuality and compulsive shopping (41, 46, 50). It is possible that patients do not mention these effects due to feelings of shame, with potential detrimental psychosocial consequences (45). In a large study by Bancos and coworkers in patients with prolactinomas with ongoing or past DA therapy compared to patients with non-functioning pituitary adenomas (NFPA) without DA therapy, the prevalence of impulse control disorders was significantly higher in prolactinoma patients (24.6% vs. 17.14%), or with regard to the general population (8.4%) (41). Thereby, men with prolactinomas treated with DAs showed a 9.9 higher risk than did men with NFPA (41). Dogansen suggested that because impulse control disorders may be prevalent in one out of six patients with prolactinoma treated with DAs, endocrinology specialists should be particularly attentive to male patients with a history of addictive behavior (51).
While giant invasive prolactinomas remain a therapeutic challenge (52–54), and DA is indicated as the primary therapy in them (55), including giant prolactinomas that cause visual field deficits (56), interdisciplinary consensus findings, along with careful MRI evaluation, are advised when it comes to the primary treatment choice in prolactinoma patients (5, 6, 35, 57). Whether transsphenoidal surgery in prolactinomas is superior to standard care as a first-line approach or a second-line treatment has to be investigated, and we will follow with interest the results of the PRolaCT trial (NCT 04107480).
Author Contributions
LA designed and wrote the article. EC contributed to the study design and critically revised the commentary. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Zielinski G, Ozdarski M, Maksymowicz M, Szamotulska K, Witek P. Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery. Front Endocrinol (Lausanne) (2020) 11:439. doi: 10.3389/fendo.2020.00439
2. Knosp E, Steiner E, Kitz K, Matula C. Pituitary Adenomas With Invasion of the Cavernous Sinus Space: A Magnetic Resonance Imaging Classification Compared With Surgical Findings. Neurosurgery (1993) 33:610–7. discussion 617–8. doi: 10.1227/00006123-199310000-00008
3. Micko AS, Wohrer A, Wolfsberger S, Knosp E. Invasion of the Cavernous Sinus Space in Pituitary Adenomas: Endoscopic Verification and its Correlation With an MRI-based Classification. J Neurosurg (2015) 122:803–11. doi: 10.3171/2014.12.JNS141083
4. Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, et al. Operative Treatment of Prolactinomas: Indications and Results in a Current Consecutive Series of 212 Patients. Eur J Endocrinol (2008) 158:11–8. doi: 10.1530/EJE-07-0248
5. Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, et al. Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health. World Neurosurg (2017) 97:595–602. doi: 10.1016/j.wneu.2016.10.059
6. Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, et al. 10-Year Follow-Up Study Comparing Primary Medical vs. Surgical Therapy in Women With Prolactinomas. Endocrine (2017) 55:223–30. doi: 10.1007/s12020-016-1115-2
7. Andereggen L, Frey J, Andres RH, Luedi MM, El-Koussy M, Widmer HR, et al. First-Line Surgery in Prolactinomas: Lessons From a Long-Term Follow-Up Study in a Tertiary Referral Center. J Endocrinol Invest (2021). doi: 10.1007/s40618-021-01569-6
8. Vermeulen E, D’Haens J, Stadnik T, Unuane D, Barbe K, Van Velthoven V, et al. Predictors of Dopamine Agonist Resistance in Prolactinoma Patients. BMC Endocr Disord (2020) 20:68. doi: 10.1186/s12902-020-0543-4
9. Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology (2019) 109:42–50. doi: 10.1159/000495775
10. Primeau V, Raftopoulos C, Maiter D. Outcomes of Transsphenoidal Surgery in Prolactinomas: Improvement of Hormonal Control in Dopamine Agonist-Resistant Patients. Eur J Endocrinol (2012) 166:779–86. doi: 10.1530/EJE-11-1000
11. Song YJ, Chen MT, Lian W, Xing B, Yao Y, Feng M, et al. Surgical Treatment for Male Prolactinoma: A Retrospective Study of 184 Cases. Med (Baltimore) (2017) 96:e5833. doi: 10.1097/MD.0000000000005833
12. Wu ZB, Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M. Five Years Follow-Up of Invasive Prolactinomas With Special Reference to the Control of Cavernous Sinus Invasion. Pituitary (2008) 11:63–70. doi: 10.1007/s11102-007-0072-4
13. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liege, Belgium. J Clin Endocrinol Metab (2006) 91:4769–75. doi: 10.1210/jc.2006-1668
14. Andereggen L, Frey J, Andres RH, Luedi MM, Widmer HR, Beck J, et al. Persistent Bone Impairment Despite Long-Term Control of Hyperprolactinemia and Hypogonadism in Men and Women With Prolactinomas. Sci Rep (2021) 11:5122. doi: 10.1038/s41598-021-84606-x
15. Honegger J, Nasi-Kordhishti I, Aboutaha N, Giese S. Surgery for Prolactinomas: A Better Choice? Pituitary (2020) 23:45–51. doi: 10.1007/s11102-019-01016-z
16. Duskin-Bitan H, Shimon I. Prolactinomas in Males: Any Differences? Pituitary (2020) 23:52–7. doi: 10.1007/s11102-019-01009-y
17. Landolt AM, Keller PJ, Froesch ER, Mueller J. Bromocriptine: Does it Jeopardise the Result of Later Surgery for Prolactinomas? Lancet (1982) 2:657–8. doi: 10.1016/S0140-6736(82)92756-8
18. Menucci M, Quinones-Hinojosa A, Burger P, Salvatori R. Effect of Dopaminergic Drug Treatment on Surgical Findings in Prolactinomas. Pituitary (2011) 14:68–74. doi: 10.1007/s11102-010-0261-4
19. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. Cabergoline Comparative Study Group. N Engl J Med (1994) 331:904–9. doi: 10.1056/NEJM199410063311403
20. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. J Clin Endocrinol Metab (1999) 84:2518–22. doi: 10.1210/jcem.84.7.5810
21. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, et al. Guidelines of the Pituitary Society for the Diagnosis and Management of Prolactinomas. Clin Endocrinol (Oxf) (2006) 65:265–73. doi: 10.1111/j.1365-2265.2006.02562.x
22. dos Santos Nunes V, El Dib R, Boguszewski CL, Nogueira CR. Cabergoline Versus Bromocriptine in the Treatment of Hyperprolactinemia: A Systematic Review of Randomized Controlled Trials and Meta-Analysis. Pituitary (2011) 14:259–65. doi: 10.1007/s11102-010-0290-z
23. Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine Agonists and Pituitary Tumor Shrinkage. Endocr Rev (1992) 13:220–40. doi: 10.1210/edrv-13-2-220
24. Landolt AM, Osterwalder V. Perivascular Fibrosis in Prolactinomas: Is it Increased by Bromocriptine? J Clin Endocrinol Metab (1984) 58:1179–83. doi: 10.1210/jcem-58-6-1179
25. Esiri MM, Bevan JS, Burke CW, Adams CB. Effect of Bromocriptine Treatment on the Fibrous Tissue Content of Prolactin-Secreting and Nonfunctioning Macroadenomas of the Pituitary Gland. J Clin Endocrinol Metab (1986) 63:383–8. doi: 10.1210/jcem-63-2-383
26. Takahashi T, Kuwayama A, Katoh T, Kageyama N. [Histological Changes and Operative Findings of Pituitary Adenomas After Bromocriptine Treatment]. Nihon Naibunpi Gakkai Zasshi (1986) 62:1336–51. doi: 10.1507/endocrine1927.62.12_1336
27. Scanarini M. [Morphological Changes in Prolactinoma Induced by Bromocriptine Treatment]. Minerva Endocrinol (1990) 15:13–5.
28. Hubbard JL, Scheithauer BW, Abboud CF, Laws ER Jr. Prolactin-Secreting Adenomas: The Preoperative Response to Bromocriptine Treatment and Surgical Outcome. J Neurosurg (1987) 67:816–21. doi: 10.3171/jns.1987.67.6.0816
29. Gen M, Uozumi T, Ohta M, Ito A, Kajiwara H, Mori S. Necrotic Changes in Prolactinomas After Long Term Administration of Bromocriptine. J Clin Endocrinol Metab (1984) 59:463–70. doi: 10.1210/jcem-59-3-463
30. Mohan N, Chia YY, Goh GH, Ting E, Teo K, Yeo TT. Cabergoline-Induced Fibrosis of Prolactinomas: A Neurosurgical Perspective. BMJ Case Rep (2017) 2017:bcr2017220971. doi: 10.1136/bcr-2017-220971
31. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia. New Engl J Med (2003) 349:2023–33. doi: 10.1056/NEJMoa022657
32. Kwancharoen R, Auriemma RS, Yenokyan G, Wand GS, Colao A, Salvatori R. Second Attempt to Withdraw Cabergoline in Prolactinomas: A Pilot Study. Pituitary (2014) 17:451–6. doi: 10.1007/s11102-013-0525-x
33. Xia MY, Lou XH, Lin SJ, Wu ZB. Optimal Timing of Dopamine Agonist Withdrawal in Patients With Hyperprolactinemia: A Systematic Review and Meta-Analysis. Endocrine (2018) 59:50–61. doi: 10.1007/s12020-017-1444-9
34. Sala E, Bellaviti Buttoni P, Malchiodi E, Verrua E, Carosi G, Profka E, et al. Recurrence of Hyperprolactinemia Following Dopamine Agonist Withdrawal and Possible Predictive Factors of Recurrence in Prolactinomas. J Endocrinol Invest (2016) 39:1377–82. doi: 10.1007/s40618-016-0483-z
35. Andereggen L, Frey J, Christ E. Long-Term IGF-1 Monitoring in Prolactinoma Patients Treated With Cabergoline Might Not be Indicated. Endocrine (2020) 72(1):216–22. doi: 10.1007/s12020-020-02557-1
36. Barber TM, Kenkre J, Garnett C, Scott RV, Byrne JV, Wass JA. Recurrence of Hyperprolactinaemia Following Discontinuation of Dopamine Agonist Therapy in Patients With Prolactinoma Occurs Commonly Especially in Macroprolactinoma. Clin Endocrinol (Oxf) (2011) 75:819–24. doi: 10.1111/j.1365-2265.2011.04136.x
37. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker-van Marle ME, Pereira AM, et al. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab (2019) 105(3):e32–41. doi: 10.1210/clinem/dgz144
38. Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM. Recurrence of Hyperprolactinemia After Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis. J Clin Endocrinol Metab (2010) 95:43–51. doi: 10.1210/jc.2009-1238
39. Donegan D, Atkinson JL, Jentoft M, Natt N, Nippoldt TB, Erickson B, et al. Surgical Outcomes of Prolactinomas in Recent Era: Results of a Heterogenous Group. Endocr Pract (2017) 23:37–45. doi: 10.4158/EP161446.OR
40. Stiles CE, Tetteh-Wayoe ET, Bestwick JP, Steeds RP, Drake WM. A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Patients With Hyperprolactinemia Treated With Cabergoline. J Clin Endocrinol Metab 104(2):523–38. doi: 10.1210/jc.2018-01071
41. Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse Control Disorders in Patients With Dopamine Agonist-Treated Prolactinomas and Nonfunctioning Pituitary Adenomas: A Case-Control Study. Clin Endocrinol (Oxf) (2014) 80:863–8. doi: 10.1111/cen.12375
42. Sosa-Eroza E, Espinosa E, Ramirez-Renteria C, Mendoza V, Arreola R, Mercado M. Treatment of Multiresistant Prolactinomas With a Combination of Cabergoline and Octreotide LAR. Endocrine (2018) 61:343–8. doi: 10.1007/s12020-018-1638-9
43. Hinojosa-Amaya JM, Johnson N, Gonzalez-Torres C, Varlamov EV, Yedinak CG, McCartney S, et al. Depression and Impulsivity Self-Assessment Tools to Identify Dopamine Agonist Side Effects in Patients With Pituitary Adenomas. Front Endocrinol (Lausanne) (2020) 11:579606. doi: 10.3389/fendo.2020.579606
44. Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, et al. Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients. J Clin Endocrinol Metab (2008) 93:4721–7. doi: 10.1210/jc.2007-2758
45. Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological Effects of Dopamine Agonist Treatment in Patients With Hyperprolactinemia and Prolactin-Secreting Adenomas. Eur J Endocrinol/Eur Fed Endocr Soc (2019) 180:31–40. doi: 10.1530/EJE-18-0682
46. Moore TJ, Glenmullen J, Mattison DR. Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs. JAMA Intern Med (2014) 174:1930–3. doi: 10.1001/jamainternmed.2014.5262
47. Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA. Valvular Heart Disease and the Use of Cabergoline for the Treatment of Prolactinoma. Clin Endocrinol (2009) 70:104–8. doi: 10.1111/j.1365-2265.2008.03458.x
48. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson’s Disease. New Engl J Med (2007) 356:39–46. doi: 10.1056/NEJMoa054830
49. Stiles CE, Tetteh-Wayoe ET, Bestwick J, Steeds RP. Drake Wm. A Meta-Analysis of the Prevalence of Cardiac Valvulopathy in Hyperprolactinemic Patients Treated With Cabergoline. J Clin Endocrinol Metab (2018) 104(2):523–38. doi: 10.1210/jc.2018-01071
50. Weiss HD, Pontone GM. Dopamine Receptor Agonist Drugs and Impulse Control Disorders. JAMA Intern Med (2014) 174:1935–7. doi: 10.1001/jamainternmed.2014.4097
51. Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al. Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab (2019) 104:2527–34. doi: 10.1210/jc.2018-02202
53. Souteiro P, Karavitaki N. Dopamine Agonist Resistant Prolactinomas: Any Alternative Medical Treatment? Pituitary (2020) 23:27–37. doi: 10.1007/s11102-019-00987-3
54. Tang H, Cheng Y, Huang J, Li J, Zhang B, Wu ZB. Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. Front Endocrinol (Lausanne) (2021) 12:616339. doi: 10.3389/fendo.2021.616339
55. Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS. Giant Prolactinoma and Effectiveness of Medical Management. Endocr Pract (2010) 16:42–6. doi: 10.4158/EP09221.OR
56. Shimon I, Benbassat C, Hadani M. Effectiveness of Long-Term Cabergoline Treatment for Giant Prolactinoma: Study of 12 Men. Eur J Endocrinol (2007) 156:225–31. doi: 10.1530/EJE-06-0646
Keywords: dopamine agonists, follow-up, Knosp grading, microadenoma, macroadenoma, prolactinoma, remission, surgery
Citation: Andereggen L and Christ E (2021) Commentary: “Prolactinomas: Prognostic Factors of Early Remission After Transsphenoidal Surgery”. Front. Endocrinol. 12:695498. doi: 10.3389/fendo.2021.695498
Received: 15 April 2021; Accepted: 30 April 2021;
Published: 14 May 2021.
Edited by:
Fabienne Langlois, Centre Hospitalier Universitaire de Sherbrooke, CanadaReviewed by:
Mark Molitch, Northwestern University, United StatesAndrea Glezer, University of São Paulo, Brazil
Copyright © 2021 Andereggen and Christ. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lukas Andereggen, lukas.andereggen@ksa.ch, orcid.org/0000-0003-1764-688X